Spots Global Cancer Trial Database for talazoparib
Every month we try and update this database with for talazoparib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | NCT04703920 | Metastatic Brea... Metastatic Cast... Metastatic Ovar... | Talazoparib Belinostat | 18 Years - | University of Michigan Rogel Cancer Center | |
| Open-Label Extension and Safety Study of Talazoparib | NCT02921919 | Cancer | Talazoparib | 18 Years - | Pfizer | |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | NCT04991480 | Advanced Cancer Metastatic Canc... Breast Cancer | ART4215 Talazoparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) | NCT04332744 | Metastatic Pros... | Enzalutamide Talazoparib | 18 Years - | MedSIR | |
| Telaglenastat + Talazoparib In Prostate Cancer | NCT04824937 | Prostate Cancer... | Telaglenastat Talazoparib | 18 Years - | Massachusetts General Hospital | |
| A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer | NCT03901469 | Triple Negative... | ZEN003694 Talazoparib | 18 Years - | Zenith Epigenetics | |
| Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | NCT03974217 | Leukemia | Talazoparib Decitabine | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | NCT04991480 | Advanced Cancer Metastatic Canc... Breast Cancer | ART4215 Talazoparib Niraparib | 18 Years - | Artios Pharma Ltd | |
| Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | NCT03990896 | Breast Cancer | Talazoparib | 18 Years - | Massachusetts General Hospital | |
| Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | NCT04846478 | Metastatic Pros... Metastatic Cast... | Talazoparib Tazemetostat | 18 Years - | Dana-Farber Cancer Institute | |
| PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours | NCT05053854 | Neuroendocrine ... | Talazoparib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes | NCT02286687 | Advanced Malign... ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Metastatic Mali... PALB2 Gene Muta... Recurrent Malig... Refractory Mali... | Laboratory Biom... Pharmacological... Talazoparib | 18 Years - | M.D. Anderson Cancer Center | |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | NCT06218628 | Primary Myelofi... Post-polycythem... Post-essential ... Chronic Myelomo... Polycythemia Ve... Essential Throm... | Talazoparib pacritinib | 18 Years - | Fox Chase Cancer Center | |
| A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer | NCT03148795 | Prostate Cancer | Talazoparib | 18 Years - | Pfizer | |
| Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | NCT04337970 | Kidney Cancer Renal Cell Carc... Unresectable Re... Metastatic Rena... | Talazoparib Axitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors | NCT03042910 | Solid Tumor | Talazoparib | 18 Years - | Pfizer | |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | NCT05059522 | Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors | Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600 | 18 Years - | Pfizer | |
| Strata PATH™ (Precision Indications for Approved Therapies) | NCT05097599 | Cancer Advanced Solid ... | lorlatinib encorafenib + b... talazoparib sacituzumab gov... axitinib | 18 Years - | Strata Oncology | |
| Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer | NCT03672773 | Recurrent Exten... Refractory Exte... | Talazoparib Temozolomide | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) | NCT01945775 | Breast Neoplasm... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | talazoparib Physician's-Cho... | 18 Years - | Pfizer | |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | NCT05873192 | Prostate Cancer | ADT Enzalutamide Talazoparib Degarelix Luprolide | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | NCT04039230 | Breast Cancer | Talazoparib Sacituzumab Gov... | 18 Years - | Massachusetts General Hospital | |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | NCT04486352 | Endometrial Can... | Atezolizumab - ... Bevacizumab Ipatasertib Talazoparib Trastuzumab emt... Tiragolumab Atezolizumab - ... Inavolisib Letrozole Giredestrant Abemaciclib | 18 Years - | Alliance Foundation Trials, LLC. | |
| Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076) | NCT05650476 | Metastatic Cast... | Talazoparib | 18 Years - | Pfizer | |
| Talazoparib Maintenance Therapy in Triple-negative Breast Cancer | NCT04755868 | TNBC - Triple-N... | Talazoparib Placebo | 19 Years - | Yonsei University | |
| A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) | NCT01945775 | Breast Neoplasm... BRCA 1 Gene Mut... BRCA 2 Gene Mut... | talazoparib Physician's-Cho... | 18 Years - | Pfizer | |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | NCT03968406 | Malignant Femal... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Vagin... Stage IV Cervic... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IV Uterin... Stage IV Vagina... Stage IVA Cervi... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVA Vagin... Stage IVB Cervi... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri... Stage IVB Vagin... | Quality-of-Life... Radiation Thera... Talazoparib | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | NCT05725200 | Metastatic Colo... | Alectinib Cetuximab Crizotinib Dasatinib Everolimus Encorafenib Gemcitabine Idelalisib Larotrectinib Methotrexate Palbociclib Panobinostat Pembrolizumab Petrozumab Trastuzumab Talazoparib Venetoclax | 18 Years - | Oslo University Hospital | |
| Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | NCT03990896 | Breast Cancer | Talazoparib | 18 Years - | Massachusetts General Hospital | |
| Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | NCT04337970 | Kidney Cancer Renal Cell Carc... Unresectable Re... Metastatic Rena... | Talazoparib Axitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial | NCT05142241 | Adrenal Gland P... Hematopoietic a... Malignant Solid... Paraganglioma | Biopsy Biospecimen Col... Computed Tomogr... Talazoparib Temozolomide | 12 Years - | National Cancer Institute (NCI) | |
| Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia | NCT04207190 | Recurrent Acute... Refractory Acut... | Gemtuzumab Ozog... Quality-of-Life... Questionnaire A... Talazoparib Talazoparib Tos... | 18 Years - | Roswell Park Cancer Institute | |
| A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | NCT04690855 | Breast Cancer Triple Negative... | Talazoparib Atezolizumab Radiation | 18 Years - | Hoosier Cancer Research Network | |
| Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies | NCT02392793 | Childhood Solid... | Talazoparib Irinotecan Temozolomide Filgrastim Peg-filgrastim | 12 Months - 25 Years | St. Jude Children's Research Hospital | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer | NCT03377556 | ATM Gene Mutati... ATR Gene Mutati... BARD1 Gene Muta... BRCA1 Gene Muta... BRCA2 Gene Muta... BRIP1 Gene Muta... CHEK1 Gene Muta... CHEK2 Gene Muta... FANCA Gene Muta... FANCC Gene Muta... FANCD2 Gene Mut... FANCF Gene Muta... FANCM Gene Muta... NBN Gene Mutati... PALB2 Gene Muta... RAD51 Gene Muta... RAD51B Gene Mut... RAD54L Gene Mut... Recurrent Squam... RPA1 Gene Mutat... Stage IV Squamo... | Laboratory Biom... Pharmacological... Talazoparib | - | SWOG Cancer Research Network | |
| A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | NCT04019327 | Prostate Cancer Prostate Adenoc... Prostate Neopla... Prostate Cancer... Castration-resi... | Talazoparib Temozolomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) | NCT02997176 | Advanced Solid ... | Talazoparib | 18 Years - | Pfizer | |
| Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma | NCT04068831 | Metastatic Rena... Fumarate Hydrat... Succinate Dehyd... | Talazoparib Avelumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Talazoparib and Thoracic RT for ES-SCLC | NCT04170946 | Lung Cancer Small-Cell Lung... | Talazoparib in ... | 18 Years - | University Health Network, Toronto | |
| Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | NCT04334941 | Extensive Stage... | Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Talazoparib | 18 Years - | National Cancer Institute (NCI) | |
| A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors | NCT04672460 | Advanced Solid ... Solid Tumors Ovarian Cancer Breast Cancer Prostate Cancer NSCLC Pancreatic Canc... Colorectal Canc... | TALZENNA capsul... Talazoparib sof... Talazoparib sof... | 18 Years - 70 Years | Pfizer | |
| Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | NCT02537561 | Solid Tumors Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Cisplatin Gemcitabine Talazoparib | 18 Years - | Washington University School of Medicine | |
| A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer | NCT02836028 | Ovarian Cancer | Talazoparib Temozolomide | 18 Years - | Pfizer | |
| Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes | NCT02286687 | Advanced Malign... ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Metastatic Mali... PALB2 Gene Muta... Recurrent Malig... Refractory Mali... | Laboratory Biom... Pharmacological... Talazoparib | 18 Years - | M.D. Anderson Cancer Center | |
| Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency | NCT04892693 | Advanced Breast... | Talazoparib Ora... | 19 Years - | Seoul National University Hospital | |
| STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS | NCT04635631 | Neoplasms | talazoparib | 18 Years - | Pfizer | |
| Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors | NCT02537561 | Solid Tumors Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Cisplatin Gemcitabine Talazoparib | 18 Years - | Washington University School of Medicine | |
| Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd | NCT04740190 | Recurrent Gliom... Recurrent Gliob... Poly ADP Ribose... PTEN Gene Inact... IDH Mutation | Talazoparib | 18 Years - | The University of Hong Kong | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial | NCT05327010 | Advanced Malign... Metastatic Mali... Unresectable Ma... | BET Bromodomain... Biopsy Biospecimen Col... Diagnostic Imag... Talazoparib | 18 Years - | National Cancer Institute (NCI) | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors | NCT03565991 | Locally Advance... Genes, BRCA 1 | Avelumab Talazoparib | 18 Years - | Pfizer | |
| Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma | NCT04462809 | Advanced Malign... | Talazoparib | 18 Years - | Hospices Civils de Lyon | |
| A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | NCT04690855 | Breast Cancer Triple Negative... | Talazoparib Atezolizumab Radiation | 18 Years - | Hoosier Cancer Research Network | |
| FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test | NCT06193525 | Advanced Breast... | Talazoparib | 18 Years - | Erasmus Medical Center | |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | NCT05059522 | Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors | Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600 | 18 Years - | Pfizer | |
| Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) | NCT04332744 | Metastatic Pros... | Enzalutamide Talazoparib | 18 Years - | MedSIR | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer | NCT04987931 | Breast Cancer | Talazoparib | 18 Years - | Pfizer | |
| Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05425862 | Metastatic Cast... | Pidnarulex Talazoparib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors | NCT03077607 | Advanced Solid ... | Talazoparib Itraconazole Rifampin | 18 Years - | Pfizer | |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | NCT04734730 | Castration-Sens... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Bicalutamide Degarelix Goserelin Aceta... Leuprolide Acet... Prednisone Questionnaire A... Talazoparib | 18 Years - | City of Hope Medical Center | |
| FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test | NCT06193525 | Advanced Breast... | Talazoparib | 18 Years - | Erasmus Medical Center | |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | NCT04734730 | Castration-Sens... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Bicalutamide Degarelix Goserelin Aceta... Leuprolide Acet... Prednisone Questionnaire A... Talazoparib | 18 Years - | City of Hope Medical Center | |
| A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer | NCT03148795 | Prostate Cancer | Talazoparib | 18 Years - | Pfizer | |
| TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer | NCT03964532 | Breast Cancer | Talazoparib Avelumab | 18 Years - | Georgetown University | |
| Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | NCT02912572 | Metastatic Endo... | Avelumab Talazoparib Axitinib | 18 Years - | Dana-Farber Cancer Institute | |
| Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | NCT05035745 | Advanced Refrac... Advanced Triple... Metastatic Trip... | Talazoparib Selinexor | 18 Years - 99 Years | National University Hospital, Singapore | |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | NCT04550494 | Advanced Pancre... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HER2-Positive B... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Brea... Metastatic Gast... Metastatic Mali... Metastatic Ovar... Metastatic Panc... Metastatic Pros... Platinum-Sensit... Stage II Pancre... Stage III Ovari... Stage III Pancr... Stage III Prost... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Talazoparib | 18 Years - | National Cancer Institute (NCI) | |
| ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer | NCT05071937 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | ZEN003694 Talazoparib | 18 Years - | University of Pittsburgh | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05425862 | Metastatic Cast... | Pidnarulex Talazoparib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | NCT03499353 | Early Breast Ca... | TALAZOPARIB | 18 Years - | Pfizer | |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | NCT05873192 | Prostate Cancer | ADT Enzalutamide Talazoparib Degarelix Luprolide | 18 Years - | M.D. Anderson Cancer Center | |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | NCT04052204 | Squamous Cell C... Metastatic Cast... | avelumab Bempegaldesleuk... talazoparib enzalutamide | 18 Years - | Pfizer | |
| Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | NCT04801966 | Cancer | Trametinib Cobimetinib Binimetinib Alpelisib Vemurafenib Dabrafenib Encorafenib Palbociclib Olaparib Ribociclib Abemaciclib Talazoparib Nivolumab Atezolizumab Pembrolizumab | 2 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer | NCT03901469 | Triple Negative... | ZEN003694 Talazoparib | 18 Years - | Zenith Epigenetics | |
| Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | NCT04173507 | Advanced Lung N... Recurrent Lung ... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Avelumab Talazoparib Talazoparib Tos... | - | SWOG Cancer Research Network |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
